Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Yoh

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
ESMO Open|July 17, 2024
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa studyS Niho, Y Goto, R Toyozawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2020
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancerR Perets, J Bar, D W Rasco, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
ESMO Open|July 17, 2024
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa studyS Niho, Y Goto, R Toyozawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2020
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancerR Perets, J Bar, D W Rasco, et al.
Pageof 5